Sonoda, H.; Takahashi, K.; Minami, K.; Hirato, T.; Yamamoto, T.; So, S.; Tanizawa, K.; Schmidt, M.; Sato, Y.
Treatment of Neuronopathic Mucopolysaccharidoses with Blood–Brain Barrier-Crossing Enzymes: Clinical Application of Receptor-Mediated Transcytosis. Pharmaceutics 2022, 14, 1240.
https://doi.org/10.3390/pharmaceutics14061240
AMA Style
Sonoda H, Takahashi K, Minami K, Hirato T, Yamamoto T, So S, Tanizawa K, Schmidt M, Sato Y.
Treatment of Neuronopathic Mucopolysaccharidoses with Blood–Brain Barrier-Crossing Enzymes: Clinical Application of Receptor-Mediated Transcytosis. Pharmaceutics. 2022; 14(6):1240.
https://doi.org/10.3390/pharmaceutics14061240
Chicago/Turabian Style
Sonoda, Hiroyuki, Kenichi Takahashi, Kohtaro Minami, Toru Hirato, Tatsuyoshi Yamamoto, Sairei So, Kazunori Tanizawa, Mathias Schmidt, and Yuji Sato.
2022. "Treatment of Neuronopathic Mucopolysaccharidoses with Blood–Brain Barrier-Crossing Enzymes: Clinical Application of Receptor-Mediated Transcytosis" Pharmaceutics 14, no. 6: 1240.
https://doi.org/10.3390/pharmaceutics14061240
APA Style
Sonoda, H., Takahashi, K., Minami, K., Hirato, T., Yamamoto, T., So, S., Tanizawa, K., Schmidt, M., & Sato, Y.
(2022). Treatment of Neuronopathic Mucopolysaccharidoses with Blood–Brain Barrier-Crossing Enzymes: Clinical Application of Receptor-Mediated Transcytosis. Pharmaceutics, 14(6), 1240.
https://doi.org/10.3390/pharmaceutics14061240